Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLECTIC
2023-506282-66-00Phase 3Authorised
- Sponsor
- Institut Curie
- Start
- Dec 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluoroestradiol f 18 in breast cancer (3 arms), sponsored by Institut Curie. Primary endpoint: Progression-free survival (PFS). Planned start Dec 2023; status: authorised.
02
Drugs
fluoroestradiol f 18
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506282-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506282-66-00.